Bristol-Myers Squibb (BMY)

Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative medicines for serious diseases. As of December 15, 2025, BMS stands at a critical juncture, balancing the impending "patent cliff" for several of its blockbuster drugs with a strategically diversified [...]

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.

These dividend investments can provide you with a growing income stream in 2026.

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results and a staggering 1,400% year-to-date rally, the French biotechnology firm has been officially crowned the most likely acquisition

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The primary driver of this turnaround has been the resolution of long-standing pricing uncertainties, as most major drugmakers

Even if you think the market will slump, selling your holdings isn't an ideal strategy.

Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors.

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its price target. 

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

These dividend growth machines could have considerable upside for long-term investors.

Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a new price target of $62. 

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.